Internal Medicine, Endocrinology, Diabetes, & Metabolism · Canfield, OH
NPI
1770589194
Since 2005
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
3694 Starrs Centre Dr
Canfield, OH, 44406
Phone (330) 702-1310
Groups this clinician bills Medicare through
Medicare paid, 2024
$179K
3,380 services
Medicare patients, 2024
943
Average age 73
Drug cost, 2024
$2.2M
4,878 prescriptions
Company payments, 2025
$2,348
From 26 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael A Derosa was code 99214 (office e&m - established), 1,217 times for 562 patients. In total Michael A Derosa billed 3,380 services in 12 codes, and Medicare paid $179K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-01-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,217 | 562 | $88.03 | $107K |
| 83036 Blood Count | Office | 917 | 440 | $9.42 | $8,637 |
| 95251 Test - Miscellaneous | Office | 520 | 228 | $25.24 | $13K |
| 99213 Office E&M - Established | Office | 432 | 338 | $55.47 | $24K |
| 76536 Ultrasound - Nonspecific | Office | 117 | 116 | $69.26 | $8,104 |
| 99204 Office E&M - New | Office | 104 | 104 | $102.02 | $11K |
| 99205 Office E&M - New | Office | 21 | 21 | $163.33 | $3,430 |
| 99443 Telephone Services | Office | 18 | 17 | $44.43 | $800 |
| 99215 Office E&M - Established | Office | 17 | 16 | $139.91 | $2,379 |
By year: 2022 $181K for 3,372 services; 2023 $176K for 3,341 services; 2024 $179K for 3,380 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 917 | 440 | $9.42 | $8,637 |
Medicare prescription drug claims, 2024
In 2024, the drug Michael A Derosa prescribed most often to Medicare patients was Levothyroxine Sodium, with 917 prescriptions and refills. In total Michael A Derosa wrote 4,878 Medicare prescriptions that cost $2.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 917 | 2,594 | 271 | $11K |
| Synthroid Levothyroxine Sodium | 426 | 1,100 | 118 | $35K |
| Ozempic Semaglutide | 259 | 402 | 60 | $382K |
| Metformin Hcl Er Metformin Hcl | 222 | 628 | 78 | $2,414 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 167 | 427 | 68 | $28K |
| Metformin Hcl Generic | 162 | 432 | 48 | $1,381 |
| Methimazole Generic | 160 | 405 | 48 | $1,078 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 150 | 400 | 66 | $14K |
| Jardiance Empagliflozin | 138 | 342 | 48 | $196K |
| Trulicity Dulaglutide | 105 | 148 | 30 | $142K |
| Rosuvastatin Calcium Generic | 88 | 218 | 30 | $1,234 |
| Januvia Sitagliptin Phosphate | 87 | 199 | 26 | $100K |
| Atorvastatin Calcium Generic | 79 | 237 | 28 | $917 |
| Humalog Kwikpen U-100 Insulin Lispro | 78 | 199 | 36 | $29K |
| Mounjaro Tirzepatide | 72 | 86 | 20 | $90K |
Brand drugs: 2,436 claims; generic drugs: 2,083 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael A Derosa $2,348 ($2,348 in general payments such as food, travel and fees) from 26 companies. The largest payer was Novo Nordisk Inc with $293.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 18 | $293 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 23 | $252 |
| Dexcom, Inc. DXCM | 4 | $219 |
| Abbvie Inc. ABBV | 13 | $203 |
| Abbott Laboratories ABT | 11 | $186 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 11 | $143 |
| Medtronic, Inc. MDT | 3 | $140 |
| Lilly USA, LLC LLY | 6 | $110 |
| Xeris Pharmaceuticals, Inc. | 5 | $98.74 |
| Ascendis Pharma Endocrinology Inc ASND | 4 | $95.44 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.